Finance

Beta
Lists
CVG:FRA
CSPC Pharmaceutical Group Ltd
€0.78
-3.21%
(-0.026) 1D
Jun 3, 8:05:12 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for CVG...
Open
€0.78
High
€0.78
Low
€0.78
Mkt. cap
83.32B
Avg. vol.
388.00
Volume
0.00
52-wk high
€1.25
52-wk low
€0.74
No. of employees
20K
Open
€0.78
High
€0.78
Low
€0.78
Mkt. cap
83.32B
Avg. vol.
388.00
Volume
0.00
52-wk high
€1.25
52-wk low
€0.74
No. of employees
20K
News stories
From sources across the web
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceutical Group Ltd
CEOZhang Cuilong
Employees19.7K
Founded1992
Headquarters-
SectorPharmaceutical industry
Websitecspc.com.hk
Previous reportsAll values in HKD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.26B
6.62B
6.11B
6.47B
Cost of goods sold
2.25B
2.28B
2.11B
2.20B
Cost of revenue
2.25B
2.28B
2.11B
2.20B
Research and development expenses
1.38B
1.50B
1.62B
1.40B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.56B
1.97B
1.87B
1.89B
Operating expense
2.94B
3.47B
3.49B
3.29B
Total operating expenses
5.20B
5.75B
5.60B
5.49B
Operating income
1.06B
869.63M
514.71M
973.82M
Other non operating income
3.60M
645.49M
-470.42M
181.80M
EBT including unusual items
1.32B
1.18B
505.59M
1.13B
EBT excluding unusual items
1.14B
1.37B
186.56M
1.13B
Income tax expense
242.36M
222.47M
165.64M
243.25M
Effective tax rate
18.34%
18.78%
32.76%
21.46%
Other operating expenses
-
-
-
-
Net income
1.07B
963.54M
370.72M
859.79M
Net profit margin
17.09%
14.56%
6.06%
13.30%
Earnings per share
-
-
-
-
Interest and investment income
95.00M
-
195.87M
-
Interest expense
-14.91M
-105.19M
-6.76M
-11.01M
Net interest expenses
80.09M
-105.19M
189.12M
-11.01M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.36B
1.14B
802.06M
1.26B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer